US-based Topica Pharmaceuticals secured $27m of series B funding yesterday from investors including Yasuda Enterprise Development Corp., a venture capital (VC) firm backed by Japan-based insurance company Meiji Yasuda Life. Also participating in the round were VC firm Prospect Venture Partners and VC fund Third Rock Ventures. The funding will be used to conduct clinical trials for Topica’s antifungal agent, Luliconazole, which will be used to treat fungal nail infections. The trials are set to commence in the first half of next year.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?